Orion Portfolio Solutions LLC Has $1.19 Million Stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Orion Portfolio Solutions LLC lifted its holdings in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 10.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 32,997 shares of the company’s stock after purchasing an additional 3,058 shares during the quarter. Orion Portfolio Solutions LLC’s holdings in SpringWorks Therapeutics were worth $1,192,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. AlphaQuest LLC raised its holdings in SpringWorks Therapeutics by 70.2% during the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock worth $36,000 after buying an additional 414 shares during the period. KBC Group NV increased its position in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after acquiring an additional 978 shares in the last quarter. Quarry LP raised its holdings in shares of SpringWorks Therapeutics by 20.0% during the third quarter. Quarry LP now owns 6,000 shares of the company’s stock worth $192,000 after acquiring an additional 1,000 shares during the period. Arizona State Retirement System raised its holdings in shares of SpringWorks Therapeutics by 7.5% during the fourth quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock worth $622,000 after acquiring an additional 1,206 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in SpringWorks Therapeutics in the 4th quarter valued at $45,000.

Insider Activity at SpringWorks Therapeutics

In other news, insider Daniel Pichl sold 29,750 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $54.36, for a total value of $1,617,210.00. Following the completion of the transaction, the insider now directly owns 50,762 shares in the company, valued at approximately $2,759,422.32. The trade was a 36.95 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saqib Islam sold 48,000 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $53.30, for a total value of $2,558,400.00. Following the sale, the chief executive officer now owns 1,002,502 shares of the company’s stock, valued at approximately $53,433,356.60. This represents a 4.57 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 440,766 shares of company stock worth $24,402,956. Company insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Stock Performance

SWTX opened at $39.09 on Friday. The business’s 50-day simple moving average is $48.71 and its 200 day simple moving average is $39.94. The firm has a market capitalization of $2.93 billion, a PE ratio of -11.23 and a beta of 0.79. SpringWorks Therapeutics, Inc. has a 52-week low of $28.21 and a 52-week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its earnings results on Thursday, February 20th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.38). The firm had revenue of $61.55 million during the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. On average, research analysts forecast that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. HC Wainwright reissued a “buy” rating and issued a $74.00 price target on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Wedbush reissued an “outperform” rating and issued a $81.00 target price on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. Evercore ISI upped their price target on SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Finally, Guggenheim decreased their price target on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating for the company in a research note on Wednesday, January 8th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $73.20.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.